Viewing nowPregabalin Capsule 150 mg (Pregabalin)
Pregabalin 150mg
Hard capsule · Prescription medication
Hana Pharmaceutical Co., Ltd.

MFDS item code 201109308 · Approved 2011.10.31 · Insurance code 657804780
Treatment of neuropathic pain, treatment of fibromyalgia, adjunctive treatment of partial-onset seizures in epilepsy
This medication is used for the treatment of peripheral and central neuropathic pain in adults. It is also used as an adjunctive treatment for patients with epilepsy who experience partial seizures, suitable both with and without secondary generalization. Additionally, it is effective in treating fibromyalgia. In summary, this medication is used for neuropathic pain, adjunctive treatment of partial seizures in epilepsy, and improvement of fibromyalgia.
This medicine is administered orally, with or without food, in 2 divided doses of the total daily dose of pregabalin. Since this medicine is primarily excreted by the kidneys, the dose should be adjusted in patients with impaired renal function. (See section ‘5. Patients with Renal Impairment’) 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on the response and tolerability of each individual patient, the dose may be increased to 300 mg/day after 3 to 7 days. If necessary, it may thereafter be increased at 7-day intervals to a maximum of 600 mg/day. 2) Central neuropathic pain Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on the response and tolerability of each individual patient, the dose may be increased to 300 mg/day after 1 week. After an additional 1 week, the dose may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered. (See section ‘4. Discontinuation of Treatment’) 2. Epilepsy Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on the response and tolerability of each individual patient, the dose may be increased to 300 mg/day after 1 week. If necessary, it may thereafter be increased at 7-day intervals to a maximum of 600 mg/day. 3. Fibromyalgia The recommended dose of this medicine for fibromyalgia is 300 mg to 450 mg/day. The initial dose is 75 mg twice daily (150 mg/day), and based on efficacy and tolerability, it may be increased to 150 mg twice daily (300 mg/day) within 1 week. For patients who do not experience sufficient benefit at a dose of 300 mg/day, the dose may be increased to 225 mg twice daily (450 mg/day) within 1 week. Clinical studies have also been conducted at a dose of 600 mg/day; however, there is no evidence of additional benefit or adequate tolerability at this dose. Considering dose-dependent adverse reactions, doses exceeding 450 mg/day are not recommended. 4. Discontinuation of Treatment Based on current clinical experience, if treatment with this medicine is discontinued, it should be withdrawn gradually over at least 1 week. 5. Patients with Renal Impairment After entering the systemic circulation, this medicine is primarily excreted by the kidneys as unchanged drug. Since the clearance of this medicine is directly affected by creatinine clearance, dose reduction in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined using the following formula. *: For women, multiply the result obtained from the above equation by 0.85. This medicine is effectively removed from plasma by hemodialysis (approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, a supplemental dose should be administered immediately after each 4-hour hemodialysis session. [Table 1]. Pregabalin dosage based on renal function Creatinine clearance (CLcr), (mL/min) Total daily dose of pregabalin a Administration regimen Initial dose (mg/day) Maximum dose (mg/day) ≥60: Initial dose 150 mg/day, maximum dose 600 mg/day, BID or TID ≥30 -<60: Initial dose 75 mg/day, maximum dose 300 mg/day, BID or TID ≥15 -<30: Initial dose 25-50 mg/day, maximum dose 150 mg/day, QD or BID <15: Initial dose 25 mg/day, maximum dose 75 mg/day, QD Supplemental dose after hemodialysis: 25 mg, maximum dose 100 mg, single dose b TID = total daily dose administered in 3 divided doses BID = total daily dose administered in 2 divided doses QD = administered once daily a: The total daily dose (mg/day) should be administered in divided doses as specified in the administration regimen. b: Supplemental dose refers to a dose administered as a single additional dose. 6. Patients with Hepatic Impairment No dose adjustment is necessary in patients with hepatic impairment. 8. Elderly patients (65 years of age and older) Dose reduction may be necessary in elderly patients with impaired renal function.
Children under 12 years of age: Administration is not recommended because there are insufficient data on safety and efficacy. Adolescent patients aged 12 to 17 years: Administration is not recommended because there are insufficient data on safety and efficacy.
This medication may increase the risk of suicidal thoughts or behaviors; it is important to immediately inform healthcare professionals of any mood changes or abnormal behavior during treatment. It should not be taken by individuals with hypersensitivity to this medication or specific genetic disorders such as lactase deficiency. Diabetes patients may experience changes in blood glucose control due to weight gain, necessitating adjustments to hypoglycemic medication. If symptoms of angioedema occur, the medication should be discontinued immediately, and caution is warranted in the elderly to prevent accidents due to dizziness or drowsiness. Changes in vision or visual disturbances may occur, so patients should consult healthcare professionals if any unusual symptoms arise. When taking this medication alone or in combination with other antiepileptic drugs, it should be done cautiously and under the direction of a healthcare professional; abrupt cessation may result in withdrawal symptoms. Due to the potential for drug abuse, patients with a history of mental disorders or drug abuse should exercise particular caution. Patients with impaired kidney function need dose adjustments, and those with heart conditions should consult healthcare providers before use. When taken with other medications that have central nervous system depressant effects, there is a risk of respiratory depression, so caution is necessary. Pregnant women should avoid use in early pregnancy due to the risk of fetal malformations, and women of childbearing potential should use effective contraception. Breastfeeding women should consider discontinuing breastfeeding or this medication due to the potential for transmission through breast milk. Dizziness or drowsiness may occur while taking this medication; therefore, it is safest to avoid driving or operating dangerous machinery. In cases of overdose, symptoms such as confusion, drowsiness, and depression may occur, and treatment such as hemodialysis may be necessary. Keep out of reach of children and avoid transferring to other containers.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a sealed container to prevent exposure to air or moisture, and it is recommended to keep it at a cool room temperature between 15 and 30 degrees Celsius.
A hard capsule with a white upper part and a white lower part, containing white powder that is white or light yellow.
30 capsules/bottle, 200 capsules/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowPregabalin 150mg
Hard capsule · Prescription medication
Hana Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 300mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Samjin Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Samjin Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Hanmi Pharm. Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Hanmi Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.